Clinical Trials Directory

Trials / Terminated

TerminatedNCT02139098

Alternative Dosing Regimens in the Pharmacotherapy of Insomnia

Phase III Study on Alternative Dosing Regimens in the Pharmacotherapy of Mild to Moderate Insomnia

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
23 (actual)
Sponsor
Philipps University Marburg · Academic / Other
Sex
All
Age
18 Years – 69 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate whether drug efficiency of zolpidem and amitriptyline can be conditioned according to learning theory in patients with primary insomnia.

Detailed description

Previous research has shown that repeated drug treatments can be regarded as conditioning processes. Sleep disorders are especially of interest to be investigated under the perspective of conditioning with drugs, since sleep quality can be defined both in terms of subjective ratings (self-rated sleep quality parameters) and objective measures (via polysomnographic assessment PSG; e.g., total sleep time, sleep onset, sleep architecture). By using two different drugs (zolpidem, amitriptyline) that modulate sleep differentially, the investigators intend to implement a conditioning paradigm in sleep disorders dissociating conditioning effects on subjective and objective sleep parameters. Both drugs should affect objective and subjective sleep parameters positively, while only amitriptyline should modulate the objectively assessed sleep architecture by REM-suppression (latency of REM-sleep onset, percentage of REM-sleep).Patients with mild to moderate insomnia will undergo a classical conditioning paradigm with one of two study medications: amitriptyline or zolpidem. After an acquisition period and a wash-out period, conditioned sleep changes are assessed in an evocation trial. During a second treatment phase of 7 days, patients receive different doses of amitriptyline (between 0mg and 50mg per night) or zolpidem (between 0mg and 5mg per night) to evaluate alternative dosing regimens in the pharmacotherapy of mild to moderate Insomnia.

Conditions

Interventions

TypeNameDescription
DRUGAmitriptyline50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
DRUGZolpidem5 mg capsule zolpidem before going to bed on 8 out of 17 nights
DRUGAmitriptyline50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
DRUGPlaceboPlacebo

Timeline

Start date
2014-05-01
Primary completion
2017-11-01
Completion
2017-11-01
First posted
2014-05-15
Last updated
2018-03-09

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT02139098. Inclusion in this directory is not an endorsement.